Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients by Mhawech-Fauceglia, Paulette et al.
RESEARCH ARTICLE Open Access
Claudin7 and moesin in endometrial
Adenocarcinoma; a retrospective study of 265
patients
Paulette Mhawech-Fauceglia
1,5*, Dan Wang
2, Shashikant Lele
3, Peter J Frederick
3, Tanja Pejovic
4 and Song Liu
2
Abstract
Background: Metastasis is the main cause of death in cancer and is a multistep process. Moesin (MSN), a member
of the ezrin-rdixin-moesin family and Claudin7 (CLDN7), a tight junction protein, both play a role in tumor cell
metastasis. Previously, we found an over-expression of MSN and under-expression of CLDN7 at the mRNA level in
uterine serous carcinoma in comparison to uterine endometrioid adenocarcinoma. The purpose of this study is to
determine the protein expression of MSN and CLDN7 in endometrial cancer (EC) and to evaluate their prognostic
value. Two hundred sixty-five patients with EC were retrieved from the archives. MSN and CLDN7 immunostaining
were performed on the tissue paraffin sections. The expression of each antibody was reported and then correlated
with clinicopathological prognostic factors including age, tumor grade, tumor stage, lympho-vascular involvement,
depth of myometrial invasion, overall survival (OS), disease free survival (DFS) and death of disease (DOD).
Results: MSN and CLDN were expressed in 46% and 52% of overall cases. We observed an association between
MSN
+ staining and tumor grade, and serous and clear cell carcinoma subtypes (p < 0.001 each). There was an
association between CLDN7
+ staining and low tumor grade and endometrioid adenocarcinoma subtype (p < 0.001
and 0.001 respectively). However, no association between MSN and CLDN7 expression and outcome including OS,
DOD, and DFS was found.
Conclusion: A significant prognostic value of MSN and CLDN7 in predicting disease outcomes in patients with EC
was not demonstrated. Nevertheless, the high percentage of EC cases with MSN and CLDN7 immunoexpression,
and their association with tumor grade and subtypes, suggests that these proteins might play a role in
tumorigenesis of endometrial adenocarcinomas. Future studies are needed to shed light on their mechanistic
properties in EC cells.
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Background
Carcinoma of the endometrium is the most frequently
diagnosed malignancy of the female genital tract and is
the fifth leading cause of cancer related deaths in
women [1]. Endometrial cancer (EC) is divided into two
tumor subtypes: type I, a generally less aggressive neo-
plasm (endometrioid, secretory and mucinous), and type
II, a more virulent type (serous, clear cell carcinoma,
and undifferentiated carcinoma). Endometrioid adeno-
carcinomas (EAC) account for more than 80% of cases,
and they tend to present as low grade, early stage
tumors with favorable outcomes. While uterine serous
carcinomas (USC) represent a minority (3-10%) of total
endometrial cancer cases, they are usually high grade
tumors with deep myometrial invasion, lymphovascular
involvement, and a more aggressive clinical course [2-4].
USC is responsible for a disproportionate number of
deaths due to the fact that most of these tumors have
already spread outside the uteri corpus. In our quest to
better understand the clinical behavior of EAC and
USC, a DNA microarray was recently conducted and
genes of interest were validated by using RT-PCR [5,6].
In this study, two genes involved in tumor cell
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the mRNA levels in USC in comparison to EAC, with
the first (moesin) overexpressed and the second (clau-
din7) under-expressed.
Metastasis is the primary cause of death and it is a
multistep process that requires invasion of the basement
membrane by tumor cells, streaming through the blood/
lymph vessels and extravasation and growth in distant
locations. Moesin or MSN (membrane organizing exten-
sion spike protein) is a member of the ERM (ezrin-
radixin-moesin) cytoskeleton-associated protein family.
This family of proteins acts as a linkage between the cell
membrane and the underlying actin cytoskeleton and it
has been implicated in maintenance of cell shape, cell
motility and membrane trafficking and tumor metastasis
[7-11]. EMR proteins share 75% sequence identity and
thus it is logical to hypothesize that like ezrin, radixin
and moesin might be involved in tumor cell migration
[9]. Furthermore, recent studies showed that moesin
knock-down increased migration, invasion and metasta-
sis in pancreatic and gastric carcinomas [12,13]. Clau-
din7 (CLDN7) belongs to the tight junction protein
family. This family is composed of 24 proteins and it is
critical for maintaining cell polarity and signal transduc-
tions. Loss of cell-cell junction is one critical step in
tumor cell metastasis [14]. Loss of claudins has been
reported in several malignancies and their expression
seems to be a prognostic marker in several cancer types
[14-16]. More specifically, loss of CLDN7 was reported
in breast carcinoma, oral squamous cell carcinoma and
colorectal carcinoma where it was found to be asso-
ciated with poor prognosis in these tumor types [17-19].
The first objective of our study was to explore the MSN
and CLDN7 protein expression in a large series of
human endometrial cancers. The second objective was
to examine the prognostic value of MSN and CLDN7 in
predicting disease outcomes in patients with EC. To our
knowledge, this is the first report to evaluate MSN and
CLDN7 in endometrial cancer patients.
Methods
Patients population
The pathology archives were searched for endometrial
adenocarcinoma cases from January 2000-December
2010. IRB approval (I-75206) was obtained. A chart
review was conducted with extraction of clinical infor-
mation including the patients’ age at the time of diagno-
sis, the surgical stage, the post-operative therapy, the
disease free survival (DFS), the site of recurrence, the
c a u s ea n dt h ed a t eo fd e a t h . All patients underwent a
surgical staging procedure including a total hysterect-
omy with bilateral salpingo-oophorectomy, with or with-
out pelvic and para-aortic lymph node dissection and
pelvic washings, depending on the tumor grade and the
clinical tumor stage. Patients were treated according to
the National Comprehensive Cancer Network (NCCN)
guidelines (http://www.cancer.gov).
Histological evaluation
All pathology specimens were reviewed by one patholo-
gist (PMF), and tumors were classified according to
World Health Organization (WHO) criteria [20]. All
slides were examined by an expert gynecologic patholo-
gist for confirmation of the histologic type, tumor size,
tumor grade, depth of myometrial invasion (MI) and
presence of lymphovascular invasion (LVI).
Immunohistochemistry
Four μm thick sections were deparaffinized with xylene,
and washed with ethanol. Sections were cooled 20 min
and incubated 10 min with 3% H2O2 to quench endo-
genous peroxidase activity. Blocking was performed
using serum-free protein block, Dakocytomation (Car-
penteria, CA) for 30 min. The sections were pretreated
with an EDTA buffer saline solution, and microwaved
for 20 min and then sections were incubated with MSN
antibody (monoclonal; 1:20000 dilution; LifeSpan Bios-
ciences, Seattle, WA, USA) and with Claudin7 (polyclo-
nal; 1:50 dilution; Zymed, San Francisco, CA, USA) for
1 h at room temperature. The diaminobenzidine com-
plex was used as a chromogen. Positive control used for
MSN was lung adenocarcinoma and for Claudin7 was
breast adenocarcinoma. Negative control slides omitting
the primary antibody were included in all assays. The
stain was membranous and cytoplasmic for both MSN
and CLDN7. The extent of immunochemical reactivity
was graded based on intensity as follows: 0 (negative), 1
+ (weak), 2+ (moderate), 3+ (strong). For the sake of
statistical analysis, negative and weak stains were
grouped as group I (negative) and moderate and strong
as group II (positive). Examples of positive and negative
cases are illustrated in Figures 1A-B.
Statistical analyses
Statistical analyses were performed by R (http://www.r-
project.org/). The clinical parameters used for modeling
are age, tumor size, histologic subtypes, myometrial
depth of invasion, LVI, FIGO grade, recurrence, status,
and survival time. To test the association between the
biomarker and the clinical parameters, Fisher’s exact
test was performed for categorical parameters and
Welch t- test was used for the continuous ones. For sur-
vival analysis, Kaplan-Meier method with log-rank test
was used to calculate the cumulative survival time, and
check both the overall survival (OS) and disease free
survival (DFS) differences between the patients with the
different biomarker status. Multivariate cox proportional
hazard model was used to determine the hazard ratio
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with each of MSN
+ and CLDN7
+ compared with those
with MSN
- and CLDN7
-. All reported p values were two
sided.
Results and discussion
The clinical and pathologic features of 265 patients with
endometrial adenocarcinoma are summarized in Table
1. All patients had surgery for endometrial cancer with
Figure 1 A Endometrioid adenocarcinoma positive for MSN antibody. The intensity of the staining is strong and it has a membranous and
cytoplasmic pattern. (magnification × 40). Figure 1B: uterine serous carcinoma with positive staining for CLDN7 (magnification x40)
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had complete follow-up information with median of 2.7
years. The distribution of clinical factors in relation to
the status of MSN and CLDN7 expression is illustrated
in Table 2. There was a strong association between
MSN
+ and high tumor grade (p <0 . 0 0 1 )a n dw i t h
tumor subtype (p < 0.001). Specifically, MSN was more
likely to be expressed in USC, CCC and carcinosarcoma
subtypes, than in endometrioid adenocarcinomas. As for
CLDN7, there was a strong association between CLDN7
+ and low tumor grade (p < 0.001) and endometrioid
subtype (p = 0.002). There was no association between
each of MSN and CLDN7 and disease outcome such as
DOD, OS, or DFS (recurrence) (Figure2A, 2B). Finally,
MSN and CLDN7 did not show any association with
lymph node metastasis.
We further explored the impact of MSN and CLDN7
on chemotherapy response. Of the 72/265 patients who
received radiation + chemotherapy or chemotherapy
alone, 39 were MSN
+ while 33 were MSN
-, and 33 were
CLDN7
+ while 39 were CLDN
-. Based on our analysis,
there was no significant independent value of MSN and
CLDN7 in predicting OS, DFS, or DOD between these
two groups (data not shown).
Metastasis is the primary cause of fatality in endome-
trial cancer. The ERM and claudins are two families of
proteins involved in the multistep tumor metastasis pro-
cess[8,9,14]. Much is known regarding ezrin and clau-
dins1-4 in endometrial cancer but the role of MSN and
CLDN7 is yet to be explored [15,21-24]. Based on pre-
vious DNA microarray analysis, we showed an up-regu-
lation of the MSN gene and a down-regulation of the
CLDN7 g e n ei nU S Ci nc o m p a r i s o nt oE A C .T h e i r
mRNA expressions were validated by qRT-PCR [5,6]. In
addition, MSN was under-expressed and CLDN7 nor-
mally expressed in HEC1A and RL95-2 cell lines (data
not shown). The present study was done in continuity
to our previous work, aiming to determine the protein
expression of each of MSN and CLDN7 in EC and to
explore their prognostic significance in a large series of
patients.
Ezrin is the only gene in the ERM family that has
been widely explored in various malignancies. Ezrin was
evaluated in EC where it was implicated in the process
of invasion in endometrial cancer cell lines [25]. In
Table 1 Clinical and pathologic features of patients.
No. of evaluable patients 265
Follow time, year
Median 2.74
Age, year
Median 65
Range 29-97
Stage
I 174(66)
II 36(14)
III 36(14)
IV 19(7)
Subtype
Endometiriod 192(73)
USC+CCC 54(20)
Carcinosarcoma 19(7)
Grade(FIGO)
1 113(43)
2 49(18)
3 103(39)
Grade(Nuclear)
1 88(33)
2 70(26)
3 107(40)
Tumor size, cm
Median(Range) 4.58(0-33)
<=2 53(20)
>2 212(80)
Depth of myometrial invasion
Median(Range) 38.52(0-100)
<=5 0 170(64)
>5 0 95(36)
Lympho-vascular involvement
no 192(72)
yes 73(28)
Lymph Node Status
yes 41(15)
no 119(45)
Not examined 105(40)
Recurrence
no 209(79)
yes 42(16)
persistent 10(4)
progression 4(1)
Status
ANED 202(76)
AWED 28(11)
DOD 22(8)
DNED 6(2)
DWED 4(2)
others 3(1)
MSN
negative 143(54)
Table 1 Clinical and pathologic features of patients.
(Continued)
positive 122(46)
Claudin7
negative 127(48)
positive 138(52)
(Data in parentheses are percentages)
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poor prognosis in FIGO stage I EAC [26]. On the
other hand, MSN is less well studied in malignancies
and the few published data showed that alteration of
MSN was present in pancreatic cancer, lung adenocar-
cinoma and oral squamous cell carcinoma [12,27,28].
To the best of our knowledge, MSN expression has
never been reported in human EC. Previous studies
showed that claudin 3 and 4 were overexpressed in
USC and they were associated with higher tumor grade
[15,23]. However, these studies failed to show an inde-
pendent value for claudin3 and 4 in predicting disease
outcome. In our current investigation, we showed that
MSN and CLDN7 proteins were expressed in a high
percentage (almost 50%) of EC cases. Furthermore, we
found a strong association of MSN and CLDN7
expressions with two important histologic prognostic
factors - tumor grade and tumor subtypes. Specifically,
MSN protein expression was associated with type II
carcinomas and high tumor grade (G3), while CLDN7
protein expression was associated with low tumor
grade (FIGO G1 and G2) and with type I carcinomas.
Even though no prognostic value of MSN and CLDN7
expression in predicting EC patient outcome was
found, the above data nevertheless led us to suggest
that MSN and CLDN7 proteins might be involved in
the tumorigenesis of endometrial cancer.
One limitation of our study was that the majority of
our tumors were endometrioid type, well differentiated,
and presented at an early stage, which is a frequent
occurrence in endometrial cancer. Because these tumors
have favorable outcome in general, it is expected that
the majority of the patient population will be alive at
the time of last follow-up. The resulting fewer numbers
of unfavorable outcome in these patients might limit
our statistical power in predicting survivals.
Conclusions
Using immunohistochemical stains, our work is the first
to comprehensively study the protein expression of
MSN and CLDN7 in correlation with the clinical char-
acteristics in a large series of patients with endometrial
cancer. Although we did not find a significant prognos-
tic value of MSN and CLDN7 in predicting disease out-
come in patients with endometrial cancer, our data
suggests that MSN and CLDN7 protein
Table 2 Association between MSN and claudin7 immunoexpression and the clinical variables
Variables (group 1 vs group2) MSN Claudin7
Pvalue Odds Ratio CI Pvalue Odds Ratio CI
Age* 0.206 0.196
Stage^ 0.29 1.401 0.741-2.664 1 1.033 0.546-1.962
Tumor size^ 0.013 2.305 1.168-4.724 0.759 0.876 0.456-1.673
Lymho-vascular involvement^ 0.098 0.616 0.344-1.096 0.413 1.255 0.707-2.236
Lymph node status 1 1.018 0.47-2.2 0.365 0.685 0.314-1.48
Depth of myometrial invasion^ 0.305 1.323 0.776-2.262 0.442 0.797 0.467-1.358
Grade_FIGO^ < 0.001 2.561 1.501-4.41 < 0.001 0.389 0.226-0.665
Grade_nuclear^ < 0.001 2.557 1.504-4.385 0.001 0.419 0.245-0.711
Subtype# < 0.001 0.311 0.154-0.609 0.002 2.628 1.353-5.253
Recurrence# 0.867 0.935 0.456-1.925 0.309 1.479 0.722-3.061
Recurrence^ 0.867 0.928 0.454-1.903 0.401 1.383 0.678-2.852
Status# 0.567 0.847 0.462-1.554 0.112 1.623 0.885-3.007
Status^ 1 1.015 0.468-2.226 0.278 1.53 0.705-3.386
^ The P-values by Fisher exact test to test the correlations between the biomarker and the clinical factors.
* The P-value is calculated by the two sample welch t-test
Stage: Group1: stages I and II; Group 2: stages III and IV
Tumor Size: Group 1:< = 2 cm; Group2: > 2 cm
LVI: Group 1:yes; Group2: no
Depth of myometrial invasion: Group1:< = 50; Group2:> 50
Grade: Group1: grade 1 and 2; Group2; grade 3
Subtype#: Group1:CCC & USC; Group 2: Endometrioid; Group3: MMMT
Recurrence#: Group1:yes; Group2:no; Group3:others
Recurrence^: Group1:yes; Group2: no &others
Status#: Group1: ANED; Group2: all others
Status^: Group1:ANED&AWED; Group2: all others
Interprete the Odds Ratio:
> 1, the proportion of p and n biomarkers status in Group 2 is greater than the proportion in Group 1
< 1, the proportion of p and n biomarkers status in Group 1 is greater than the proportion in Group 2
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ment and progression of carcinoma of the endometrium.
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